Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Fig. 3

a. 5-year disease-free survival (DFS) in patients with PDL-1 (≥1%), 62.5%, vs PDL-1 (< 1%), 39.5%; p = 0.141. b. 5-year disease-specific survival (DSS) in patients with PDL-1 (≥1%), 67.2%, vs PDL-1 (< 1%), 50.4%; p = 0.132. c. 5-year disease-free survival (DFS) in patients with CTLA4-High*, 63.7%, vs CTLA4-Low, 36.5%; p = 0.043 (* > 15% & any moderate/strong staining if < 15%). d. 5-year disease-specific survival (DSS) in patients with CTLA4-High, 70.5%, vs CTLA4-Low, 43.2%; p = 0.017

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us